We are Healthy
U.S.

Pediatric Eustachian Tube Registry Reached 100 Patients

A new observational study is tracking the long-term clinical performance of an FDA-cleared balloon dilation system for children.

Updated on Sept. 29, 2026 in Allergies

Isometric editorial illustration of a medical ear anatomy model, representing a clinical study for pediatric medical device tracking.
Integra LifeSciences has enrolled 100 pediatric patients in a multicenter registry to evaluate the clinical performance of the Acclarent AERA balloon dilation system. AI Illustration. Upload story photo >

Live Poll

Does real-world registry data from medical companies increase your trust in new medical devices?

Integra LifeSciences has enrolled 100 pediatric patients in a multicenter registry evaluating the Acclarent AERA Eustachian Tube Balloon Dilation System. This prospective study follows children aged eight and older who suffer from obstructive Eustachian tube dysfunction.

Why it matters

This registry is designed to generate essential real-world evidence regarding the performance of this medical device in a pediatric population. It helps clinicians better understand the outcomes of this treatment as use expands to children since the system's 2023 FDA clearance.

The AERA Pediatric Registry is a prospective multicenter observational study that has enrolled 100 participants to date. It is currently evaluating children aged eight and older, with a total enrollment target of 300 patients to assess the clinical performance of the device.

The players

Integra LifeSciences

A medical technology company that develops surgical and regenerative medicine solutions, including the Acclarent line of ear, nose, and throat devices.

The details

The Acclarent AERA system uses a balloon dilation mechanism to physically open the Eustachian tube, which is designed to relieve obstruction and restore proper ventilation to the middle ear. The registry tracks how this device performs in real-world clinical settings across the United States. By observing children undergoing this procedure, researchers aim to collect data on the effectiveness of the treatment for pediatric patients struggling with chronic Eustachian tube dysfunction.

Timeline

  1. December 2023: The AERA system received FDA clearance for pediatric use.

  2. July 2025: The AERA Pediatric Registry officially launched.

  3. September 29, 2026: The 100th patient was enrolled in the registry.

Health Landscape

The AERA Pediatric Registry functions as an essential framework for establishing standardized outcomes in pediatric otolaryngology. It represents a broader trend in medical device regulation toward gathering post-market, real-world data specifically for children to complement initial regulatory approval.

If your child suffers from chronic Eustachian tube dysfunction, this registry highlights ongoing efforts to refine treatment options in pediatric care. Discuss the current standard of care and whether a procedure like balloon dilation is a potential option for your child with your pediatrician or an ENT specialist.

The takeaway

This registry is actively working to provide clearer clinical expectations for pediatric balloon dilation procedures. Families should talk with their physician to determine if an ENT specialist is the right expert to help navigate chronic ear symptoms in children.

Further reading

For more on managing ear-related health concerns, visit the Allergies section of our site.

Live Poll

Does real-world registry data from medical companies increase your trust in new medical devices?